NCT01164150 2026-04-13
Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06
Cancer Trials Ireland
Phase 2 Terminated
Clinical Trials
24 trialsNCT05036681 2026-03-27
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05798611 2025-11-06
ARTIST
Artios Pharma Ltd
Phase 2 Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT05263492 2025-10-02
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT04527900 2025-06-19
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
University of Maryland, Baltimore
Phase 2 Terminated
NCT05523440 2025-03-28
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
Phase 2 Terminated
NCT04750941 2025-03-04
Study of Copanlisib and Ketogenic Diet
Columbia University
Phase 2 Terminated
NCT03099499 2024-12-24
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Fox Chase Cancer Center
Phase 2 Terminated
NCT04743999 2024-03-29
Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma
Henry Ford Health System
Phase 2 Terminated
NCT04511026 2023-10-11
Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
Stanford University
Phase 2 Terminated
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT03642990 2023-04-12
NR in Chemo-induced Peripheral Neuropathy
University of Iowa
Phase 2 Terminated
NCT03077698 2022-06-07
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
Xenetic Biosciences, Inc.
Phase 2 Terminated
NCT00900562 2021-10-28
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
PharmaMar
Phase 2 Terminated
NCT01251354 2019-01-14
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
Ipsen
Phase 2 Terminated
NCT01420081 2019-01-08
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Pfizer
Phase 2 Terminated
NCT01184053 2017-06-14
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00671606 2016-05-27
Hysteroscopic Lymphatic Mapping for Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02002689 2016-05-02
SIGNATURE
Novartis
Phase 2 Terminated
NCT00470067 2014-08-22
Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00003179 2013-06-10
Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer
GOG Foundation
Phase 2 Terminated
NCT00003624 2013-04-11
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
GOG Foundation
Phase 2 Terminated